Show simple item record

dc.contributor.authorLakhani, SRen_US
dc.contributor.authorvan de Vijver, MJen_US
dc.contributor.authorJacquemier, Jen_US
dc.contributor.authorAnderson, TJen_US
dc.contributor.authorOsin, PPen_US
dc.contributor.authorMcGuffog, Len_US
dc.contributor.authorEaston, DFen_US
dc.contributor.authorConsortium, BCLen_US
dc.date.accessioned2018-09-18T10:35:49Z
dc.date.issued2002-05-01en_US
dc.identifier9en_US
dc.identifier.citationJOURNAL OF CLINICAL ONCOLOGY, 2002, 20 pp. 2310 - 2318en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2762
dc.identifier.doi10.1200/JCO.2002.09.023en_US
dc.description.abstractPurpose : The morphologic and molecular phenotype of breast cancers may help identify patients who are likely to carry germline mutations in BRCA1 and BRCA2. This study evaluates the immunohistochemical profiles of tumors arising in patients with mutations in these genes. Materials and Methods: Samples of breast cancers obtained from the International Breast Cancer Linkage Consortium were characterized morphologically and immunohistochemically using antibodies to estrogen receptor, progesterone receptor, HER-2 (c-erbB-2 oncogene), and p53 protein. Results: Breast cancers in patients with BRCA1 germline mutations are more often negative for estrogen receptor, progesterone receptor, and HER-2, and are more likely to be positive for p53 protein compared with controls. In contrast, BRCA2 tumors do not show a significant difference in the expression of any of these proteins compared with controls. Conclusion: BRCA1 has a distinctive morphology and immunohistochemical phenotype. The combined morphologic and immunohistochemical data can be used to predict the risk of a young patient harboring a germline mutation in BRCA1. The BRCA2 phenotype is currently not well defined. (C) 2002 by American Society of Clinical Oncology.en_US
dc.format.extent2310 - 2318en_US
dc.titleThe pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1200/JCO.2002.09.023en_US
rioxxterms.licenseref.startdate2002-05-01en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJOURNAL OF CLINICAL ONCOLOGYen_US
pubs.notesresearcherid-numbers: Lakhani, Sunil/I-1970-2018 orcid-numbers: Lakhani, Sunil/0000-0003-4067-2760 unique-id: ISI:000175370500014en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Molecular Pathology
pubs.volume20en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMolecular Pathologyen_US
dc.contributor.icrauthorLakhani, Sunilen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record